Stellar Teens - CNTO1275PSO4056 - NIS
Laufzeit: 01.01.2018 - 31.12.2024
Kurzfassung
An observational post-authorization safety of ustekinumab in the treatment of pediatric patients aged 12 years and older with moderate to severe plaque psoriasis.
Laufzeit: 01.01.2018 - 31.12.2024
An observational post-authorization safety of ustekinumab in the treatment of pediatric patients aged 12 years and older with moderate to severe plaque psoriasis.
